P-148. A Practical Antibiogram for Community-Acquired Gastroenteritis in British Columbia, Canada

Abstract Background Hospital microbiology laboratories do not routinely allow testing for community gastrointestinal stool pathogens in hospitalized patients who develop diarrhea after day 3 of hospitalization. In contrast, community microbiology laboratories routinely test and collect data of gastrointestinal stool pathogens, including their antimicrobial susceptibility profiles. The current study aimed to generate a practical antibiogram based on bacterial stool culture and susceptibility results collected in regional community microbiology laboratories in British Columbia (BC), Canada. Methods LifeLabs BC microbiology laboratories, connected with 129 collection centres in urban and rural communities in the province, provided the laboratory data for the fecal bacterial pathogens. An audit was conducted from January 1, 2020 to December 31, 2023. Calculations were performed as per the Clinical and Laboratory Standards Institute M39 document (2022). Results ORGANISM Ampicillin Trimethoprim-Sulfamethoxazole Ciprofloxacin Tetracycline Azithromycin Ceftriaxone Aeromonas species, % susceptible R 96 99 99 98 n = 677 664 664 774 Campylobacter jejuni/coli, % susceptible R R 55 65 100 n = 55 55 59 Salmonella species#, % susceptible 91 94 85 @ 99 n = 326 292 318 338 Shigella species, % susceptible 19 12 21 31 91 n = 243 225 230 113 243 Vibrio species, % susceptible R 97 100 97 @ n = 32 37 37 Yersinia species, % susceptible R 100 99 99 100 n = 822 878 927 980 R = The organism is intrinsically resistant to the antibiotic indicated OR is not recommended due to poor clinical response and/or poor activity @ = Azithromycin may be a reasonable treatment option for Salmonella and Vibrio infections when clinically indicated; however, LifeLabs has not tested enough isolates to generate a meaningful antibiogram. Conclusion Multidrug and extended-drug resistant Salmonella species do not appear to be a current problem in British Columbia. Choosing the optimal oral antimicrobial agent for Shigella species is a challenge as sensitivities of oral agents were 50%. Disclosures All Authors: No reported disclosures